Skip to content. | Skip to navigation

Personal tools

Home > Medical Center > Department Resources > Clinical Practice Guidelines, Protocols & Pathways > Clinical Practice Guidelines > IdaruCIZUMAB (Praxbind) Guidelines

guideline 2.142 : IdaruCIZUMAB (Praxbind) Guidelines

The Pharmacy and Therapeutics (P&T) Committee has approved Praxbind® for the reversal of the target specific oral anticoagulant dabigatran. The following guidelines are meant to assist users with the safe and effective use of this agent. [contact Surabhi Palkimas]

File Attachment Downloads

view  |  PDF document icon Praxbind-Guidelines-050516.pdf — PDF document, 196 KB (201518 bytes)

  1. effective date:

nav - root (DO NOT EDIT)